MA46855A - Inhibiteurs de magl - Google Patents
Inhibiteurs de maglInfo
- Publication number
- MA46855A MA46855A MA046855A MA46855A MA46855A MA 46855 A MA46855 A MA 46855A MA 046855 A MA046855 A MA 046855A MA 46855 A MA46855 A MA 46855A MA 46855 A MA46855 A MA 46855A
- Authority
- MA
- Morocco
- Prior art keywords
- magl inhibitors
- magl
- inhibitors
- Prior art date
Links
- 102100029814 Monoglyceride lipase Human genes 0.000 title 1
- 101710116393 Monoglyceride lipase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423102P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46855A true MA46855A (fr) | 2021-05-19 |
Family
ID=62145825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046855A MA46855A (fr) | 2016-11-16 | 2017-11-15 | Inhibiteurs de magl |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11059822B2 (enExample) |
| EP (1) | EP3541820B1 (enExample) |
| JP (1) | JP7042468B2 (enExample) |
| KR (1) | KR20190080935A (enExample) |
| CN (1) | CN110267962B (enExample) |
| AU (1) | AU2017361253B2 (enExample) |
| BR (1) | BR112019009880A2 (enExample) |
| CA (1) | CA3043617A1 (enExample) |
| CL (1) | CL2019001336A1 (enExample) |
| CO (1) | CO2019004945A2 (enExample) |
| CR (1) | CR20190239A (enExample) |
| DO (1) | DOP2019000118A (enExample) |
| EA (1) | EA038150B1 (enExample) |
| EC (1) | ECSP19034535A (enExample) |
| ES (1) | ES2952582T3 (enExample) |
| IL (1) | IL266547B (enExample) |
| JO (1) | JOP20190107A1 (enExample) |
| MA (1) | MA46855A (enExample) |
| MX (1) | MX389627B (enExample) |
| NI (1) | NI201900049A (enExample) |
| PE (1) | PE20191145A1 (enExample) |
| PH (1) | PH12019501079A1 (enExample) |
| RU (1) | RU2019115784A (enExample) |
| TN (1) | TN2019000149A1 (enExample) |
| UA (1) | UA125523C2 (enExample) |
| WO (1) | WO2018093949A1 (enExample) |
| ZA (1) | ZA201903099B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017197192A1 (en) * | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| AU2017361257B2 (en) | 2016-11-16 | 2022-02-10 | H. Lundbeck A/S. | Crystalline forms of a MAGL inhibitor |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| WO2018093950A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| LT3630744T (lt) | 2017-05-23 | 2023-03-10 | H. Lundbeck A/S | Pirazolo magl inhibitoriai |
| MX2020002251A (es) | 2017-08-29 | 2020-07-20 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso. |
| US11161856B2 (en) | 2017-08-29 | 2021-11-02 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
| JP2021531287A (ja) * | 2018-07-19 | 2021-11-18 | ファイザー・インク | Ｍａｇｌ阻害剤としての複素環式スピロ化合物 |
| BR112021002298A2 (pt) | 2018-08-13 | 2021-05-04 | F. Hoffmann-La Roche Ag | compostos heterocíclicos como inibidores da monoacilglicerol lipase |
| IL297470A (en) | 2020-04-21 | 2022-12-01 | H Lundbeck As | Synthesis of a monoacylglycerol lipase inhibitor |
| UY39516A (es) | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| US12378219B2 (en) | 2022-05-04 | 2025-08-05 | H. Lundbeck A/S | Crystalline forms of a MAGL inhibitor |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1003002A (en) | 1910-10-10 | 1911-09-12 | Gustave J Martel | Tire-patching device. |
| MXPA03008109A (es) | 2001-03-07 | 2003-12-12 | Pfizer Prod Inc | Moduladores de la actividad de receptores de quimiocinas. |
| JP2009514935A (ja) * | 2005-11-05 | 2009-04-09 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
| CA2665804A1 (en) | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| CA2716863A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| FR2941696B1 (fr) | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| US8575296B2 (en) | 2009-09-29 | 2013-11-05 | Polyone Corporation | Polyester articles having simulated metallic or pearlescent appearance |
| DK3093291T3 (da) | 2009-10-23 | 2019-07-29 | Janssen Pharmaceutica Nv | Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer |
| WO2011109277A1 (en) | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| MX350788B (es) * | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| JP2014005245A (ja) * | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
| RS59512B1 (sr) | 2012-09-25 | 2019-12-31 | Hoffmann La Roche | Derivati heksahidropirolo[3,4−c]pirola i srodna jedinjenja kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za lečenje npr. bubrežnih bolesti |
| CA2917050A1 (en) | 2013-07-03 | 2015-01-08 | Todd K. Jones | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| AP2016009496A0 (en) * | 2014-04-04 | 2016-10-31 | X-Rx Inc | Substituted spirocydic inhibitors of autotaxin |
| US10093630B2 (en) | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US9771341B2 (en) | 2015-03-18 | 2017-09-26 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| US10450302B2 (en) | 2015-05-11 | 2019-10-22 | Lundbeck La Jolla Research Center, Inc. | Methods of treating inflammation or neuropathic pain |
| WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| CN108601769B (zh) | 2015-11-20 | 2021-09-03 | H.隆德贝克有限公司 | 吡唑化合物及其制备和使用方法 |
| SG11201807539UA (en) | 2016-03-31 | 2018-09-27 | Takeda Pharmaceuticals Co | Heterocyclic compound |
| WO2017197192A1 (en) * | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190049A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| WO2018093950A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| AU2017361257B2 (en) | 2016-11-16 | 2022-02-10 | H. Lundbeck A/S. | Crystalline forms of a MAGL inhibitor |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| NZ756915A (en) | 2017-03-13 | 2023-03-31 | Lundbeck La Jolla Research Center Inc | Dual magl and faah inhibitors |
| LT3630744T (lt) | 2017-05-23 | 2023-03-10 | H. Lundbeck A/S | Pirazolo magl inhibitoriai |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| MX2020002251A (es) | 2017-08-29 | 2020-07-20 | Lundbeck La Jolla Research Center Inc | Compuestos espirociclicos y sus metodos de preparacion y uso. |
| US11161856B2 (en) | 2017-08-29 | 2021-11-02 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
| UY39516A (es) | 2020-11-13 | 2022-05-31 | H Lundbeck As | Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión |
-
2017
- 2017-06-16 JO JOP/2019/0107A patent/JOP20190107A1/ar unknown
- 2017-11-15 RU RU2019115784A patent/RU2019115784A/ru unknown
- 2017-11-15 KR KR1020197017201A patent/KR20190080935A/ko not_active Ceased
- 2017-11-15 ES ES17871458T patent/ES2952582T3/es active Active
- 2017-11-15 WO PCT/US2017/061870 patent/WO2018093949A1/en not_active Ceased
- 2017-11-15 CR CR20190239A patent/CR20190239A/es unknown
- 2017-11-15 PE PE2019001017A patent/PE20191145A1/es unknown
- 2017-11-15 MA MA046855A patent/MA46855A/fr unknown
- 2017-11-15 US US16/349,047 patent/US11059822B2/en active Active
- 2017-11-15 JP JP2019523671A patent/JP7042468B2/ja active Active
- 2017-11-15 BR BR112019009880A patent/BR112019009880A2/pt not_active IP Right Cessation
- 2017-11-15 EP EP17871458.0A patent/EP3541820B1/en active Active
- 2017-11-15 TN TNP/2019/000149A patent/TN2019000149A1/en unknown
- 2017-11-15 EA EA201991029A patent/EA038150B1/ru unknown
- 2017-11-15 MX MX2019005773A patent/MX389627B/es unknown
- 2017-11-15 CN CN201780083651.3A patent/CN110267962B/zh active Active
- 2017-11-15 CA CA3043617A patent/CA3043617A1/en not_active Abandoned
- 2017-11-15 UA UAA201905617A patent/UA125523C2/uk unknown
- 2017-11-15 AU AU2017361253A patent/AU2017361253B2/en not_active Ceased
-
2019
- 2019-05-12 IL IL266547A patent/IL266547B/en unknown
- 2019-05-14 DO DO2019000118A patent/DOP2019000118A/es unknown
- 2019-05-14 CO CONC2019/0004945A patent/CO2019004945A2/es unknown
- 2019-05-15 PH PH12019501079A patent/PH12019501079A1/en unknown
- 2019-05-15 EC ECSENADI201934535A patent/ECSP19034535A/es unknown
- 2019-05-16 NI NI201900049A patent/NI201900049A/es unknown
- 2019-05-16 CL CL2019001336A patent/CL2019001336A1/es unknown
- 2019-05-17 ZA ZA2019/03099A patent/ZA201903099B/en unknown
-
2021
- 2021-06-09 US US17/343,227 patent/US11691975B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3541932A4 (en) | INHIBITORS OF CRISPR-CAS9 | |
| MA46855A (fr) | Inhibiteurs de magl | |
| MA46857A (fr) | Inhibiteurs de magl | |
| MA52635A (fr) | Inhibiteurs de magl | |
| DK3405050T3 (da) | Børnesikret snusbeholder | |
| EP3541822A4 (en) | MAGL INHIBITORS | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| EP3313828A4 (en) | METALLO-BETA-Lactamase INHIBITORS | |
| DK3436823T3 (da) | Antigen-array | |
| EP3394068A4 (en) | TDO2 INHIBITORS | |
| PT3630744T (pt) | Inibidores de pirazol magl | |
| DK3445708T3 (da) | Stigbøjle | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| DK3509963T3 (da) | Pallecontainer | |
| MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
| MA46889A (fr) | Inhibiteurs de gsk-3 | |
| DK3575238T3 (da) | Pallecontainer | |
| DE112017000734A5 (de) | Glycolsensor | |
| DK3323708T3 (da) | Bovfender | |
| DK3481826T3 (da) | Tyrosinkinaseinhibitorer | |
| EP3528810A4 (en) | BROMDOMAIN INHIBITOR | |
| DK3452587T3 (da) | Penicillin-g-acylaser | |
| DK3430609T3 (da) | Smartflag | |
| DK3471535T3 (da) | Dyrelift |